Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer.
about
Second-Line Therapy for Advanced NSCLCEstablishment of a first‑line second‑line treatment model for human pulmonary adenocarcinomaA Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung CancerMeta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary studyPopulation pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptomsTreatment of advanced non small cell lung cancer.The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.Lung cancer: Biology and treatment options.Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesRandomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancerDose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.Weekly low-dose docetaxel for salvage chemotherapy in pretreated elderly or poor performance status patients with non-small cell lung cancer.Docetaxel in the treatment of advanced non-small-cell lung cancer.Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorptionNew avenues for second-line treatment of metastatic non-small-cell lung cancer.Focus on Nintedanib in NSCLC and Other TumorsHistorical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Tubulin inhibitors in non-small cell lung cancer: looking back and forward.Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysisThe safety of second-line treatment options for non-small cell lung cancer.Prospective analysis on survival outcomes of nonsmall cell lung cancer stages over IIIb treated with HangAm-Dan.Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207†.Taxane-Induced Peripheral Neurotoxicity.Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small-cell lung cancer.Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis.Lessons learned from development of docetaxel
P2860
Q27002398-A5BEB7D7-6F12-4EDC-87A0-49807E8D04ABQ28468342-CCA44596-CCBC-4FE3-9A43-D088583F48B9Q30317149-C0FFDDBB-9951-4631-B155-232BB83A47C1Q31036511-7AE9F0ED-8409-4042-A3B7-91F32DC57CDAQ33301768-31DE4FDC-A661-4DF9-A38F-DA208307BFCCQ33795052-63A40A1D-E2DB-4E9B-BC29-B3DADD4474D8Q33886036-B3FA9C6B-48E8-4F9C-8303-8414ED4CA8E6Q35667817-749BB1B7-513B-4FFB-9233-7DD7C73EEF2AQ36142491-24D9DC05-CBED-4B92-B596-8187CCFD35F3Q36328370-04466B26-11A0-417D-B153-41D4AC382452Q36412597-D98A8342-CEFA-42B1-B629-2DF5098579B8Q36557454-A43ECAA2-E296-4983-AA43-E4E761A5A5E5Q36622084-746B9418-3585-4789-80CD-44E22EC29EF7Q37030260-0E0635B4-1AF2-47B9-AD5D-0494C449149BQ37242661-A3F51B71-F2DF-4566-8AD4-3657853C9F5CQ37256120-A8CBB974-9B07-4FDB-8596-C67DB5F65EDCQ37357304-589BA32D-511D-4732-B92C-DA6B99BC08DFQ37512962-7C6B1721-E459-452C-96F9-8AFAA8611B86Q37598057-81D54BFD-D473-410A-AA26-116DBF57A5CEQ37945643-1D018245-5AF5-4625-A4EA-4AFF9D11AB78Q38742506-0A229DA8-4478-472D-8C5D-BA850B2360CBQ38847914-DFD72560-EA4E-40BF-84B4-B6971DC2846CQ39139831-20E42489-F488-4385-A246-C8626EF7A492Q39170310-ABB02CA6-C88A-45E9-906E-B5A55B1FB243Q39816573-7BBEE1F4-E16D-4068-86D5-4B29F1ABF7C4Q44685863-844A4079-98AE-48E4-8A5A-77CED387D317Q45759415-7701AFDD-A6A2-4AB5-8424-0920F5144442Q47861831-40A8E4C0-E577-4836-B510-1E3F6A3921ACQ48549299-000CD99E-25E6-44A7-8140-63A50E31CF81Q50089508-DF776A8F-15B2-45E9-AD09-2E8B23A343EDQ51043526-5EBB816A-827C-4B44-BD48-678E61195722Q51591928-01F0B58B-023C-430E-BD47-A1256744E368Q54411624-ACE37E33-7850-4FED-9296-34E66B257C3BQ55516981-33817D56-5CC8-4DC8-BF7C-67C92BE429F6Q58382477-D3B962EB-2778-44F1-A7E0-D19918FB35F1
P2860
Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Individual patient data meta-a ...... ed non-small-cell lung cancer.
@ast
Individual patient data meta-a ...... ed non-small-cell lung cancer.
@en
type
label
Individual patient data meta-a ...... ed non-small-cell lung cancer.
@ast
Individual patient data meta-a ...... ed non-small-cell lung cancer.
@en
prefLabel
Individual patient data meta-a ...... ed non-small-cell lung cancer.
@ast
Individual patient data meta-a ...... ed non-small-cell lung cancer.
@en
P2093
P50
P356
P1476
Individual patient data meta-a ...... ed non-small-cell lung cancer.
@en
P2093
Chun-Ming Tsai
Elisabeth Quoix
Francesco Perrone
P304
P356
10.1200/JCO.2006.09.8251
P407
P577
2007-04-01T00:00:00Z